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Abstract  1 
 2 
Objectives: Adherence to antiretroviral therapy (ART) leads to viral suppression for people 3 
living with HIV (PLHIV) and is critical for both individual health and reducing onward HIV 4 
transmission. HIV-stigma is a risk factor that can undermine adherence. We explored the 5 
association between HIV-stigma and self-reported ART adherence among PLHIV in 21 6 
communities in the HPTN 071 (PopART) trial in Zambia and the Western Cape of South 7 
Africa. 8 
 9 
Methods: We conducted a cross-sectional analysis of baseline data collected between 10 
2013-2015, before the roll out of trial interventions. Questionnaires were conducted and 11 
consenting participants provided a blood sample for HIV testing. Poor adherence was 12 
defined as self-report of not currently taking ART, missing pills over the previous 7 days or 13 
stopping treatment in the previous 12 months. Stigma was categorised into three domains: 14 
community, health setting and internalised stigma. Multivariable logistic regression was used 15 
for analysis. 16 
 17 
Results: Among 2,020 PLHIV self-reporting ever taking ART, 1888 (93%) were included in 18 
multivariable analysis. Poor ART adherence was reported by 15.8% (n=320) of participants, 19 
25.7% (n=519) reported experiencing community stigma, 21.5% (n=434) internalised stigma 20 
and 5.7% (n=152) health-setting stigma. PLHIV who self-reported previous experiences of 21 
community and internalised stigma more commonly reported poor ART adherence than 22 
those who did not (aOR 1.63, 95%CI 1.21 -2.19, p=0.001 and aOR 1.31, 95%CI 0.96-1.79, 23 
p=0.09).  24 
 25 
Conclusions: HIV-stigma was associated with poor ART adherence. Roll-out of universal 26 
treatment will see an increasingly high proportion of PLHIV initiated on ART. Addressing HIV 27 
stigma could make an important contribution to supporting lifelong ART adherence. 28 
 29 
 30 
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 32 
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For people living with HIV (PLHIV), adherence to antiretroviral therapy (ART) is crucial for 3 
viral suppression 1-3 and reducing HIV-related morbidity and mortality 4, onward transmission 4 
5-7 and drug resistance 8. UNAIDS 90-90-90 targets captured the importance of achieving 5 
high levels of HIV testing and ART coverage, with the “third 90” target being that by 2020 6 
90% of those on ART were virally suppressed 9. In 2016, an estimated 89% of PLHIV in 7 
Zambia who reported current ART use 10, and 85% of those registered in HIV care and 8 
taking ART in South Africa 11 were virally suppressed. Understanding the factors that 9 
influence adherence to ART is crucial if high levels of viral suppression are to be sustained 10 
and increased.  11 
 12 
HIV-stigma can undermine ART adherence 12-17 and is a frequently reported barrier to 13 
adherence in sub-Saharan Africa 13. HIV-stigma is common in both Zambia and South 14 
Africa, with over 35% of PLHIV reporting some type of stigma 18. While ART adherence is 15 
consistently found to be worse among individuals experiencing stigma than among those 16 
who do not 19-25, a 2013 review concluded that all but one study was at risk of bias, and most 17 
had not used validated exposure or outcome measures 19. Currently, data come mostly from 18 
facility-based or purposively sampled populations, and there is heterogeneity in the 19 
measurement of both ART adherence and HIV-stigma.  20 
 21 
We analysed baseline data from the HPTN 071 (PopART) trial 26,27 to explore the 22 
association between HIV-stigma and ART adherence for adults with HIV in a random 23 
population sample from 21 urban and peri-urban communities in Zambia and the Western 24 
Cape of South Africa. Data were collected between 2013-2015, after more than 10 years of 25 
scale-up of HIV treatment services and ART in both countries. We explored these 26 
associations among individuals who started ART prior to the implementation of the PopART 27 




HPTN071 (PopART) was a cluster-randomised trial conducted in Zambia and South Africa 3 
to assess the impact of a combination of HIV prevention interventions, including household-4 
based HIV testing and an offer of universal ART initiation regardless of CD4 count or clinical 5 
stage for those testing HIV-positive, on HIV infection rates. Twenty-one urban communities 6 
were purposively selected for inclusion in the trial if they had a heath facility offering HIV and 7 
TB services, high HIV prevalence and a population of >20,000. In each country, study 8 
communities were matched in triplets based on HIV prevalence and geographic proximity, 9 
and then randomised to one of three trial arms 26,27.  10 
 11 
Between November 2013 and March 2015 approximately 2000 individuals were enrolled in 12 
each study community as a ‘population cohort’ to assess the effect of trial interventions on 13 
primary and secondary outcomes. From a simple random sample of households, household 14 
members were enumerated and one adult (18-44 years) per household randomly selected 15 
for inclusion in the cohort. Selected adults were asked for consent to enrol in the study and 16 
participate in a baseline survey and three follow up surveys. For those giving consent, a 17 
venous blood sample was taken and analysed in-country using a single fourth generation 18 
serologic assay. A second fourth generation assay was used to confirm HIV-positive results 19 
and any discrepancies tested with additional assays to confirm HIV status. The baseline 20 
survey was conducted using face-to-face interviewer administered questionnaires, with data 21 
collected on electronic devices. Participants were asked about their HIV status and if they 22 
were happy to do so, share the results of their last HIV test. All participants were offered an 23 
on-the-spot rapid HIV test.  24 
 25 
Our analysis was restricted to individuals who self-reported living with HIV, with confirmation 26 
from the laboratory HIV testing. Among this group, individuals were included if they reported 27 
ever starting ART before the 1st January 2014. We excluded participants if they had no 28 
information on the year of starting ART, or reported starting ART for the prevention of 29 
mother to child transmission of HIV (PMTCT) but were no longer taking it, as this may have 30 
been due to earlier initiation guidelines and not reflect non-adherence.  We excluded 31 
respondents if they had incomplete outcome data or missing data on all stigma questions. 32 
 33 
We created a primary outcome variable from three survey questions on ART adherence. We 34 
defined poor adherence as ‘respondents self-reporting that they had ever started ART but 35 
were not currently taking ART, or currently taking ART but had either stopped in the past 12 36 
months, or missed pills in the past seven days’. To explore whether our findings were 37 
 7 
sensitive to our primary definition of adherence we looked at a secondary outcome, 1 
restricting our definition to those reporting they were currently taking ART but had missed 2 
taking pills in the previous seven days. Both outcome variables were binary.  3 
 4 
We used 11 survey questions on HIV-stigma to generate composite ‘yes/no’ binary variables 5 
for experienced community stigma, experienced health-setting stigma and current 6 
internalised stigma. Composite variables were only generated for participants responding to 7 
all stigma questions contributing to that variable. Reponses on internalised stigma were 8 
given on a 4-point Likert scale (0=strongly disagree, 1=disagree, 2=agree, 3=strongly 9 
agree), and later aggregated for each question (0/1=disagree. 2/3=agree). Questions on 10 
community and health-setting stigma used pre-coded response categories capturing the 11 
frequency of experiences during the last year (0=never, 1=once, 2=a few times, 3=often, 12 
4=not applicable because no one knows my status (‘never disclosed’)). Those responding 13 
‘never’ or ‘never disclosed’ were categorised as ‘never experiencing either community or 14 
health-setting stigma’. To create the three variables, respondents who disagreed or never 15 
experienced stigma on all the questions related to that variable were grouped as ‘never 16 
experiencing’ that type of stigma. Those agreeing or experiencing stigma on ≥1 question 17 
were categorised as ‘ever experiencing’ that type of stigma 18. Our stigma measures were 18 
aligned with standardised measures that were approved by the UNAIDS’ monitoring and 19 
evaluation reference group (MERG) in 2014 18,28,29 20 
 21 
A priori knowledge on risk factors for ART adherence informed decisions on other 22 
explanatory variables to explore for inclusion in analysis. We considered demographic 23 
variables (country, community/study triplet, gender, age and marital status), socio-economic 24 
factors (education, wealth, employment status and food security), mobility factors (nights 25 
spent away from home), behavioural factors (alcohol and drug use) and HIV-specific factors 26 
(year of HIV diagnosis, time on ART, hiding pills (responding to the question “Have you ever 27 
hidden your ART pills so that others couldn’t see them”), HIV status disclosure and reason 28 
for starting ART). For alcohol use we categorised respondents using scores from the WHO 29 
Alcohol Use Disorders Identification Test (AUDIT) 30 and for wealth we used quintiles 30 
derived using principal component analysis. The group identified at lowest risk of the 31 
outcome was used as the reference category. Where this was unclear, we used the group 32 
with the largest numbers. 33 
 34 
We developed a conceptual framework (Figure 1) to structure our analysis using a 35 
hierarchical approach 31 based on previous work conceptualising HIV-stigma 32 and 36 
 8 
associations between stigma and ART adherence 19. We conducted analyses for the study 1 
population and then separately for each country.  2 
 3 
[Insert] Figure 1: Conceptual Framework 4 
 5 
We first described our study participants. Second, we described the distribution of ART 6 
adherence, HIV-stigma and other explanatory variables. Third, we used logistic regression to 7 
estimate unadjusted associations between HIV-stigma and ART adherence. We also 8 
estimated unadjusted associations between the other covariates and ART adherence and 9 
did the same for HIV-stigma to understand potential confounding factors and identify 10 
variables to consider further in multivariable models. We conducted an analysis of the 11 
association between HIV-stigma and ART adherence, stratified on the other explanatory 12 
variables that were considered a priori confounders, and also those showing evidence of 13 
associations (p<0.05) with adherence from our earlier unadjusted analysis.  14 
 15 
Last, we conducted an adjusted analysis using multivariable logistic regression. We included 16 
groups of variables in our models in the stages identified in our conceptual framework, in 17 
order of their proximity to the outcome. Variables were included if they were considered 18 
potential confounders, either a priori and/or those showing an unadjusted association 19 
(p<0.05) with the outcome. We excluded variables from our model if they were perceived to 20 
be on the causal pathway between stigma and ART adherence. To control for confounding 21 
by community-level factors we adjusted for study community (in Zambia) and study triplet (in 22 
South Africa) in all multivariable analysis. Study triplet was used instead of community in 23 
South Africa due to small numbers in the study population for several communities. The 24 
same series of models were built for each of the three stigma variables. We considered 25 
internalised stigma proximal to ART adherence and community and health setting stigma 26 
distal, adjusting a final set of models for each of the experienced stigmas (health setting and 27 
community) to account for this. We ran our models again with our restricted outcome 28 
definition (only those reporting they were currently taking ART but had missed taking pills in 29 
the previous seven days).  30 
 31 
Written informed consent was obtained for all respondents enrolled in the population cohort. 32 
Ethics approval was obtained for the HPTN 071 (PopART) trial from the University of 33 
Zambia, Stellenbosch University, London School of Hygiene and Tropical Medicine. 34 
 35 
  36 
 9 
Results  1 
 2 
Our analysis initially included 2020 PLHIV (Zambia n=1099; South Africa n=921) (Figure 2). 3 
The number of individuals per community ranged from three to 250, with a higher proportion 4 
of women (88.6%) than men (11.4%). 76.6% of the study population were over the age of 5 
30, and 6.3% aged 18-24 years. Approximately half the population (49%) were married or 6 
living as married, but with a higher proportion in Zambia (62.3%) than South Africa (33.1%). 7 
Upper secondary school or University education was reached by 45.5% of respondents, 8 
although this proportion was notably higher in South Africa (70.1%) than Zambia (24.8%). 9 
Similar proportions of the study population were diagnosed with HIV each year, from before 10 
2007 up until 2012. Only 6.4% of respondents were initiated on ART prior to 2005, with 11 
>60% starting ART after 2010 in both countries. Disclosure of HIV status (to friends, a 12 
religious leader, a health worker, family, or a partner) was high, at 96.4% and 97.7% for 13 
Zambia and South Africa respectively. 28% of the study population reported hiding their ART 14 
pills, with a higher proportion in Zambia (40.7%) than South Africa (12.9%). Missing data on 15 
all variables was minimal, ranging from 0-2.5% in Zambia and 0-2.7% in South Africa (Table 16 
1). 17 
 18 
[Insert] Figure 2: Study Population  19 
[Insert] Table 1: Study Population Characteristics 20 
 21 
Poor adherence to ART was reported by 320 (15.8%) respondents, with similar country 22 
specific findings (Zambia n=186, 16.9%; SA n=134, 14.5%). Most of those categorised as 23 
poor adherers reported ‘missing pills in the past seven days’ (n=244). Thirty-two 24 
respondents reported that they were not currently taking ART and 80 respondents reported 25 
stopping in the previous 12 months. Poor adherence was slightly higher for men (18.7%) 26 
than women (15.5%), with similar distributions in each country (Table 2).  27 
 28 
[Insert] Table 2: Distribution of ART adherence and HIV-stigma 29 
 30 
Stigma experienced in the community was most frequently reported (overall 25.7%; Zambia 31 
28.8%; SA 21.9%), then internalised stigma (overall 21.5%; Zambia 23.4%; SA 19.2%). 32 
Stigma experienced in health care settings was less frequently reported (overall 7.5%; 33 
Zambia 6%; SA 9.3%) (Table 2) 34 
 35 
Among the total study population those reporting stigma experienced in the community or 36 
internalised stigma were more likely to be non-adherent than those who did not, with 37 
 10 
unadjusted ORs of 1.68 (95%CI 1.29-2.18, p<0.001) and 1.52 (95%CI 1.15-2.01, p=0.003) 1 
respectively. Those experiencing health setting stigma were only slightly more likely to be 2 
non-adherent to ART than those who did not (OR 1.19, 95%CI 0.76-1.85, p=0.45). Country 3 
specific estimates were similar. In Zambia, those experiencing community stigma had 1.89 4 
(95%CI 1.35-2.65, p<0.001) the odds of poor adherence, and those reporting internalised 5 
stigma 1.62 (95%CI 1.13-2.3, p=0.008) the odds of poor adherence. In South Africa, the 6 
association between each of community and internalised stigma and poor adherence, gave 7 
ORs of 1.32 (95%CI 0.85-2.05, p=0.22) and 1.34 (95%CI 0.85-2.11, p=0.21) respectively 8 
(Table 4). 9 
 10 
In the total study population, poor ART adherence was associated with explanatory variables 11 
including community/triplet (p<0.001), higher alcohol consumption (p<0.001), lower 12 
educational attainment (p=0.04), increased mobility (p<0.001) and hiding pills (p=0.03). Of 13 
these, community/triplet showed strong evidence of an association with all three stigma 14 
variables (all p<0.001). Higher alcohol consumption was associated with internalised stigma 15 
(p<0.001) and hiding pills was associated with both internalised and health setting stigma 16 
(p<0.001 and p=0.02 respectively), but there was no evidence of an association with 17 
experienced community stigma (p=0.73). These associations differed slightly in each 18 
country, for example, there was evidence that education was associated with poor 19 
adherence in South Africa but not Zambia, and mobility in Zambia but not South Africa 20 
(Table 3). 21 
 22 
[Insert] Table 3: Logistic regression estimates of odds ratios for each variable with ART 23 
adherence 24 
 25 
Stigma experienced in the community was more likely to be reported by those who had 26 
disclosed their HIV status to their family (OR 1.42 95%CI 1.08-1.87, p=0.01), or friends (OR 27 
1.38 95%CI 1.05-1.81, p=0.02). There was little evidence that food security was associated 28 
with ART adherence (OR 1.03 95%CI 0.75-1.42, p=0.83), but strong evidence that those 29 
experiencing HIV-stigma were more likely to be food insecure than those who did not 30 
(community, OR 1.88, 95%CI 1.53-2.32, p<0.001, internalised, OR 1.72 95%CI 1.38-2.14, 31 
p<0.001 and health setting, OR 95%CI, p=0.02). 32 
 33 
Multivariable analysis was restricted to individuals with complete data on all variables (Total 34 
n=1888; Zambia n=1034, South Africa n=854). After adjusting for the potential confounding 35 
effects of demographic, socio-economic, mobility and behavioural factors, and for the other 36 
domains of stigma in line with our conceptual framework, there remained strong evidence of 37 
 11 
an association between experienced community stigma and ART adherence (aOR 1.63, 1 
95%CI 1.21 -2.19, p=0.001) but not internalised stigma and ART adherence (aOR 1.31, 2 
95%CI 0.96-1.79, p=0.09) or health setting stigma and ART adherence (aOR 1.05; 95%CI 3 
0.64-1.72; p=0.86) (Table 4).  4 
 5 
[Insert] Table 4: Logistic regression estimates of odds ratios for each stigma variable and 6 
ART adherence 7 
 8 
In Zambia, there was strong evidence of an association between stigma experienced in the 9 
community poor adherence (aOR 2.03, 95%CI 1.40-2.94, p<0.001), weak evidence of an 10 
association between internalised stigma and poor adherence (aOR 1.44; 95%CI 0.97-2.14; 11 
p=0.09) and no evidence of an association between health setting stigma and poor 12 
adherence (aOR 0.80; 95%CI 0.39-1.65; p=0.54) (Table 4). 13 
 14 
In South Africa, there was a stronger association between health setting stigma and ART 15 
adherence than in Zambia, although the evidence for this association was weak (aOR 1.66 16 
95%CI 079-3.47, p=0.18). For community and internalised stigma odds ratios were close to 17 
1, and there was no evidence of associations with either (Table 4).  18 
 19 
Although the odds of poor adherence for those reporting stigma experienced in the 20 
community were different in each country (aOR 2.03 in Zambia vs aOR 1.01 in South 21 
Africa), there was only weak evidence that these associations were different (p=0.08).  22 
There was no evidence that the associations for health setting stigma and ART adherence 23 
(p=0.38) and internalised stigma and ART adherence (p=0.57) differed in Zambia and South 24 
Africa.  25 
 26 
We conducted further analysis, restricting our outcome to individuals reporting they were 27 
currently on ART (n=1861), and defining non-adherence as missing pills in the previous 7 28 
days. Findings from our adjusted models for the whole study population were similar to our 29 
primary definition of ART adherence (community stigma aOR 1.60 95% CI 1.15-2.22 30 
p=0.005, internalised stigma aOR 1.28 95% CI 0.90-1.81, p=0.17; health setting stigma aOR 31 
0.86 96% CI 0.48-1.53 p=0.60) (Supplementary Table 1).     32 
  33 
 12 
Discussion  1 
 2 
Among a large population sample of PLHIV reporting ever taking ART in the 21 communities 3 
included in the HPTN 071 (PopART) study in Zambia and South Africa, 16% reported one or 4 
more of missing pills in the previous seven days (12%), currently taking ART but having 5 
stopped during the previous 12 months (4%), or no longer taking ART (2%). Approximately 6 
25% reported ever experiencing community stigma, 20% internalised stigma and 8% health 7 
setting stigma. PLHIV reporting stigma experienced in the community were more than 1.5 8 
times more likely to report poor ART adherence than those who did not.  9 
 10 
In Zambia, participants reporting experiences of community stigma were twice as likely to 11 
report poor adherence as those who did not, but we saw no such association in South 12 
Africa. Although there was only weak evidence that these associations were different in each 13 
country, it is also possible that they represent the different contexts. HIV stigma and poor 14 
adherence were both more common in Zambian than South African study communities. In 15 
the South Africa, a strong history of community led HIV treatment advocacy and awareness 16 
could have mitigated HIV-stigma and its effect on ART adherence. 17 
 18 
Health setting stigma was less frequently reported and may play a less important role in 19 
adherence because people generally take their pills away from a health facility. In both 20 
countries, the association between internalised stigma and ART adherence was partly 21 
explained after adjustments were made for experienced stigma in community or health 22 
settings. We hypothesised that stigma experienced in the community may itself cause 23 
internalised stigma. 24 
 25 
Our findings are similar to previous cross-sectional studies looking at stigma and ART 26 
adherence 19-25, yet direct comparisons are challenging due to variation in the specific 27 
measures used to look at these concepts. Variation also exists in the statistical adjustments 28 
made when investigating these associations. We made our own theoretical assumptions on 29 
factors to include in our multivariable models. Alcohol was considered a potential 30 
confounder, as it has been in other studies exploring these associations 19,22,33. Some 31 
studies have however identified alcohol as a means of coping with HIV status 19, 32 
compromising ability to adhere to treatment. Similarly, wealth was treated as a confounding 33 
factor in our analysis, but the relationship between economic security and HIV-related 34 
stigma is likely to be more complicated and potentially ‘mutually reinforcing’ 19. We did not 35 
treat hiding pills and HIV-status disclosure as confounders in our multivariable models as we 36 
suggest these variables lie on the causal pathway between experience of stigma and ART 37 
 13 
adherence. Including either of these variables in our models made little difference to the 1 
associations we saw between stigma and ART adherence.  Hiding pills has been frequently 2 
reported in Zambia and South Africa 34 and with strong unadjusted associations seen in this 3 
study, would be useful to explore in further work on stigma related to HIV treatment.  4 
 5 
Ours was a large study, we used validated measures of HIV-stigma 29, and measured a 6 
large number of characteristics providing the opportunity for a thorough assessment of 7 
potential confounding.  We looked at the association between three stigma “domains” on 8 
adherence to ART, giving an opportunity to identify the specific areas of stigma that had the 9 
strongest associations with ART adherence. We interpreted our findings based on a 10 
conceptual framework that considered some of the latest thinking on HIV-stigma, enabling 11 
wider comparison and contributing to existing work in this field. A composite measure of 12 
ART adherence was used to ensure inclusion of poor adherence over a year, in line with our 13 
stigma measures. In a systematic review of self-report measures, seven-day recall was most 14 
commonly used and considered effective due to the inclusion of a shorter time period, whilst 15 
covering a weekend (where adherence is often lower), but longer recall also considered 16 
important for allowing greater variability in adherence 35. We acknowledge that our 17 
composite adherence outcome could measure slightly different concepts, but tested this 18 
using a restricted outcome in our analysis and found similar results. There were relatively 19 
few missing data. 20 
 21 
There were also limitations. Our study communities were purposively sampled, and although 22 
we consider our findings generalisable to socio-economically disadvantaged, peri-urban 23 
communities with high HIV prevalence in Zambia and the Western Cape of South Africa 27,36, 24 
the generalisability of our findings to other sub-Saharan African settings may be limited. The 25 
greater proportion of women in our study population was reflective of the overall population 26 
cohort and the higher HIV prevalence among women (26%) than men (12%) 27, rather than a 27 
selection bias among individuals who had ever taken ART. Yet this disparity limits the 28 
generalisability of our findings to men, who in previous research have shown worse ART 29 
adherence than women 15,37. Our analysis excluded individuals who were not aware of or not 30 
willing to report their HIV status, and those who reported no date for starting ART. 31 
Experiences of stigma may have been different among those not willing to disclose their HIV 32 
status to our research team, and may have led to an underestimation of HIV-stigma and of 33 
its association with ART adherence. Underreporting of poor ART adherence was possible 34 
due to it being contrary to clinical guidance. However, the extent of under-reporting to our 35 
research team was unlikely to differ according to an individual’s experience of stigma, and 36 
so it is unlikely to have introduced bias to our findings. Additionally, our findings of 37 
 14 
approximately 84% adherence are compatible with viral suppression data on a random sub-1 
sample of individuals who were HIV-positive at the time of the baseline survey; these data 2 
indicated that approximately 90% of HIV-positive individuals who were taking ART were 3 
virally suppressed 27. Other factors also relied on self-report and were potentially prone to 4 
either under or over-reporting (e.g. alcohol consumption and wealth). Stigma questions 5 
specifically relating to HIV treatment 38 may have given a more specific indication of 6 





Our analysis has provided additional evidence that HIV-related stigma is associated with 12 
poor ART adherence and has identified the relative importance of the different types and 13 
components of stigma among a large sample of PLHIV across 21 communities in Zambia 14 
and South Africa. If we are to reach viral suppression among 90% of people on ART by 15 
2020, and 95% by 2030, it will be important to learn whether interventions that reduce HIV-16 
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Outcome   
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Fear of disclosure:  Non - disclosure, Hiding  
pills  
Potential confounders   
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3. Mobility:  Nights away from home    
4. Behavioral:  Alcohol, Drug Use    
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All PopART baseline respondents 
n=38,691 
Ever started ART 
n=2,821 
Confirmed HIV+ at baseline 
(self-report and HIV+ test) 
n=4,073 
Not tested (n=21), missing 
(n=1336), HIV negative self-
report (n=23,419) and/or HIV 
negative test (n=29,194) 
Never started ART (or no data 
available on this variable) 
(n=1252) 
Started taking ART before 2014 
n=2044 
Currently taking ART, or if not 
currently taking ART then didn’t 
cite PMTCT as a reason 
for ART initiation 
n=2032 
Study Population for analysis 
n=2020 
Started ART after 01/01/2014 
(n=568) or not data on ART 
start date (n=209) 
Started ART for PMTCT and 
not currently taking ART 
(n=12) 
No data on any of the 






Table 1: Study Population Characteristics 
  Total study population  Zambia South Africa 
  n n/2020 % n n/1099 % n n/921 % 
Demographic characteristics             
 Gender       
 Female 1790 88.6% 950 86.4% 840 91.2% 
 Male 230 11.4% 149 13.6% 81 8.8% 
 Age       
 18-24 128 6.3% 76 6.9% 52 5.6% 
 25-29 344 17.0% 165 15.0% 179 19.4% 
 30-34 521 25.8% 272 24.7% 249 27.0% 
 35-39 567 28.1% 310 28.2% 257 27.9% 
 >40 459 22.7% 275 25.0% 184 20.0% 
 Missing 1 0.0% 1 0.1%  0.0% 
 Study Triplet        
  - - 258 23.5% 529 57.4% 
  - - 278 25.3% 292 31.7% 
  - - 291 26.5% 100 10.9% 
  - - 272 24.7%   
 Marital status        
 Married 990 49.0% 685 62.3% 305 33.1% 
 Divorced/Separated 246 12.2% 214 19.5% 32 3.5% 
 Widowed 146 7.2% 127 11.6% 19 2.1% 
 Never married 636 31.5% 73 6.6% 563 61.1% 
 Missing 2 0.1% 0 0.0% 2 0.2% 
Socioeconomic characteristics             
 Wealth quintile       
 1 – Lowest 536 26.5% 295 26.8% 241 26.2% 
 2 426 21.1% 173 15.7% 253 27.5% 
 3 422 20.9% 219 19.9% 203 22.0% 
 4 408 20.2% 249 22.7% 159 17.3% 
 5 – Highest 223 11.0% 163 14.8% 60 6.5% 
 Missing 5 0.2% 0 0.0% 5 0.5% 
 Education       
 None/Primary 558 27.6% 468 42.6% 90 9.8% 
 Lower Secondary 527 26.1% 354 32.2% 173 18.8% 
 Upper Secondary/ University 919 45.5% 273 24.8% 646 70.1% 
 Missing  16 0.8% 4 0.4% 12 1.3% 
 Currently working       
 No 1494 74.0% 802 73.0% 692 75.1% 
 Yes 526 26.0% 297 27.0% 229 24.9% 
 Food security       
 No 1225 60.6% 605 55.1% 432 46.9% 
 Yes 793 39.3% 489 44.5% 487 52.9% 
 Missing 2 0.1% 5 0.5% 2 0.2% 
Mobility characteristics             
 Nights away from home †       
 No 1685 83.4% 876 79.7% 809 87.8% 
 Yes 322 15.9% 216 19.7% 106 11.5% 
 Missing 13 0.6% 7 0.6% 6 0.7% 
Behavioural characteristics             
 Alcohol Audit score       
 Score 0-7 1771 87.7% 967 88.0% 804 87.3% 
 Score 8-15 155 7.7% 85 7.7% 70 7.6% 
 Score 16+ 42 2.1% 20 1.8% 22 2.4% 
 Missing 52 2.6% 27 2.5% 25 2.7% 
 Drug use (past 12 months)       
 No 1988 98.4% 1076 97.9% 912 99.0% 
 Yes 22 1.1% 16 1.5% 6 0.7% 
 Missing 10 0.5% 7 0.6% 3 0.3% 
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HIV specific characteristics             
 Year of HIV diagnosis        
 Before 2009 421 20.8% 170 15.5% 251 27.3% 
 2007-2008 334 16.5% 176 16.0% 158 17.2% 
 2009-2010 438 21.7% 260 23.7% 178 19.3% 
 2011-2012 436 21.6% 261 23.8% 175 19.0% 
 2013-2014 275 13.6% 165 15.0% 110 11.9% 
 Missing 116 5.7% 67 6.1% 49 5.3% 
 First started ART       
 1996-2005 130 6.4% 69 6.3% 61 6.6% 
 2006-2009 593 29.4% 323 29.4% 270 29.3% 
 2010-2011 500 24.8% 283 25.8% 217 23.6% 
 2012-2013 797 39.5% 424 38.6% 373 40.5% 
 Hiding pills       
 No 1445 71.5% 645 58.7% 800 86.9% 
 Yes 566 28.0% 447 40.7% 119 12.9% 
 Missing 9 0.4% 7 0.6% 2 0.2% 
HIV status disclosure             
 Disclosed to anyone       
 No 61 3.0% 40 3.6% 21 2.3% 
 Yes 1959 97.0% 1059 96.4% 900 97.7% 
 Disclosed to friends       
 No 1711 84.7% 980 89.2% 731 79.4% 
 Yes 309 15.3% 119 10.8% 190 20.6% 
 Disclosed to religious leader       
 No 1969 97.5% 1064 96.8% 905 98.3% 
 Yes 51 2.5% 35 3.2% 16 1.7% 
 Disclosed to health care worker       
 No 1892 93.7% 1020 92.8% 872 94.7% 
 Yes 128 6.3% 79 7.2% 49 5.3% 
 Disclosed to family       
 No 406 20.1% 235 21.4% 171 18.6% 
 Yes 1614 79.9% 864 78.6% 750 81.4% 
 Disclosed to partner       
 No 1024 50.7% 505 46.0% 519 56.4% 
 Yes 996 49.3% 594 54.0% 402 43.6% 
Primary reason for starting ART             
 Started for PMTCT       
 No 1760 87.1% 958 87.2% 802 87.1% 
 Yes 260 12.9% 141 12.8% 119 12.9% 
 Recommend by health worker       
 No 1330 65.8% 616 56.1% 714 77.5% 
 Yes 690 34.2% 483 43.9% 207 22.5% 
 Started to protect partner        
 No 1828 90.5% 973 88.5% 855 92.8% 
 Yes 192 9.5% 126 11.5% 66 7.2% 
 Started for own health       
 No 938 46.4% 473 43.0% 465 50.5% 
  Yes 1082 53.6% 626 57.0% 456 49.5% 
† >1 in the past 3 months           
 1 
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Table 2: Distribution of ART adherence and HIV-stigma 
    Total study population Zambia South Africa 
 ART Adherence   n n/2020 % n n/1099 % n n/921 % 
Currently taking ART Yes 1,988 98.4% 1092 99.4% 896 97.3% 
 No 32 1.6% 7 0.6% 25 2.7% 
Stopped ART in the past 12 months Yes 80 4.0% 36 3.3% 44 4.8% 
 No 1,908 94.5% 1056 96.1% 852 92.5% 
 Missing 32 1.6% 7 0.6% 25 2.7% 
Missed pills in the past 7 days Yes 244 12.1% 153 13.9% 91 9.9% 
 No 1,744 86.3% 939 85.4% 805 87.4% 
  Missing 32 1.6% 7 0.6% 25 2.7% 
ART adherence Yes 1,700 84.2% 913 83.1% 787 85.5% 
  No 320 15.8% 186 16.9% 134 14.5% 
HIV Stigma               
I have lost respect or standing in the 
community because of my HIV status 
Disagree 1,732 85.7% 919 83.6% 813 88.3% 
Agree 258 12.8% 161 14.6% 97 10.5% 
Missing 30 1.5% 19 1.7% 11 1.2% 
I think less of myself 
Disagree 1,763 87.3% 952 86.6% 811 88.1% 
Agree 240 11.9% 137 12.5% 103 11.2% 
Missing 17 0.8% 10 0.9% 7 0.8% 
I have felt ashamed because of my HIV 
status 
Disagree 1,758 87.0% 945 86.0% 813 88.3% 
Agree 242 12.0% 141 12.8% 101 11.0% 
Missing 20 1.0% 13 1.2% 7 0.8% 
Internalised Stigma  
No  1,552 76.8% 819 74.5% 733 79.6% 
Yes 434 21.5% 257 23.4% 177 19.2% 
Missing 34 1.7% 23 2.1% 11 1.2% 
People have talked badly about me 
because of my HIV status 
None 1,617 80.0% 846 77.0% 771 83.7% 
Some 382 18.9% 238 21.7% 144 15.6% 
Missing 21 1.0% 15 1.4% 6 0.7% 
I have been verbally insulted, harassed 
and/or threatened because of my HIV 
status 
None 1,803 89.3% 972 88.4% 831 90.2% 
Some 200 9.9% 116 10.6% 84 9.1% 
Missing 17 0.8% 11 1.0% 6 0.7% 
I have been physically assaulted because 
of my HIV status 
None 1,899 94.0% 1046 95.2% 853 92.6% 
Some 106 5.2% 43 3.9% 63 6.8% 
Missing 15 0.7% 10 0.9% 5 0.5% 
Someone else disclosed my HIV status 
without my permission 
None 1,682 83.3% 904 82.3% 778 84.5% 
Some 314 15.5% 184 16.7% 130 14.1% 
Missing 24 1.2% 11 1.0% 13 1.4% 
I have felt that people have not wanted to 
sit next to me because of my HIV status 
None 1,915 94.8% 1060 96.5% 855 92.8% 
Some 89 4.4% 31 2.8% 58 6.3% 
Missing 16 0.8% 8 0.7% 8 0.9% 
Experienced stigma in the community 
No  1,468 72.7% 764 69.5% 704 76.4% 
Yes 519 25.7% 317 28.8% 202 21.9% 
Missing 33 1.6% 18 1.6% 15 1.6% 
Healthcare workers talked badly about me 
because of my HIV status 
Disagree 1,905 94.3% 1050 95.5% 855 92.8% 
Agree 99 4.9% 39 3.5% 60 6.5% 
Missing 16 0.8% 10 0.9% 6 0.7% 
A health worker disclosed my HIV status 
without my permission 
Disagree 1,909 94.5% 1054 95.9% 855 92.8% 
Agree 91 4.5% 35 3.2% 56 6.1% 
Missing 20 1.0% 10 0.9% 10 1.1% 
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I have been denied health services 
because of my HIV status 
Disagree 1,939 96.0% 1081 98.4% 858 93.2% 
Agree 65 3.2% 10 0.9% 55 6.0% 
Missing 16 0.8% 8 0.7% 8 0.9% 
Experienced stigma in health settings 
  
Disagree 1,844 91.3% 1020 92.8% 824 89.5% 
Agree 152 7.5% 66 6.0% 86 9.3% 














% OR 95% CI p-value† 
Demographic            
Gender       
Female 1,790 277 15.5% 1  0.22 
Male 230 43 18.7% 1.26 (0.88-1.79)  
Age       
18-24 128 19 14.8% 0.97 (0.56-1.68) 0.50 
25-29 344 66 19.2% 1.32 (0.91-1.91)  
30-34 521 79 15.2% 0.99 (0.70-1.41)  
35-39 567 86 15.2% 0.99 (0.71-1.40)  
>40 459 70 15.3% 1   
Study Triplet       
Zambia - 1 258 53 20.5% 1  <0.001 
Zambia - 2 278 46 16.5% 0.77 (0.50-1.19)  
Zambia - 3 291 63 21.6% 1.07 (0.71-1.61)  
Zambia - 4 272 24 8.8% 0.37 (0.22-0.63)  
SA - 5 529 65 12.3% 0.54 (0.36-0.81)  
SA - 6 292 49 16.8% 0.78 (0.51-1.20)  
SA - 7 100 20 20.0% 0.97 (0.54-1.72)  
Socioeconomic           
Wealth quintile       
1 - Lowest 536 83 15.5% 1  0.06 
2 426 70 16.4% 1.07 (0.76-1.52)  
3 422 50 11.8% 0.73 (0.50-1.07)  
4 408 73 17.9% 1.19 (0.84-1.68)  
5 - Highest 223 44 19.7% 1.34 (0.90-2.01)  
Missing 5 5     
Education       
None/Primary 558 84 15.1% 1  0.04 
Lower Secondary 527 103 19.5% 1.37 (1.00-1.88)  
Upper Secondary/ University 919 133 14.5% 0.95 (0.71-1.28)  
Mobility           
Nights away       
No 1,685 249 14.8% 1  0.002 
Yes 322 71 22.0% 1.63 (1.21-2.19)  
Behavioural            
Alcohol Audit score‡       
Score 0-7 1,771 253 14.3% 1  <0.001 
Score 8-15 155 40 25.8% 2.09 (1.42-3.06)  
Score 16+ 42 14 33.3% 3.00 (1.56-5.78)  
Drug use (past 12 months)       
No 1,988 308 15.5% 1  0.06 
Yes 22 7 31.8% 2.55 (1.03-6.29)  
HIV specific            
Hiding pills       
No 1,445 212 14.7% 1  0.03 
Yes 566 105 18.6% 1.32 (1.02-1.71)   
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HIV status disclosure       
No 61 12 19.7% 1  0.42 
Yes 1,959 308 15.7% 0.76 (0.40-1.45)  
Year of HIV diagnosis        
Before 2007 421 64 15.2% 1  0.43 
2007-2008 334 45 13.5% 0.87 (0.58-1.31)  
2009-2010 438 70 16.0% 1.06 (0.73-1.53)  
2011-2012 436 80 18.3% 1.25 (0.87-1.80)  
2013-2014 275 47 17.1% 1.15 (0.76-1.74)  
First started ART       
1996-2005 130 20 15.4% 0.87 (0.52-1.45) 0.46 
2006-2009 593 84 14.2% 0.79 (0.59-1.06)  
2010-2011 500 78 15.6% 0.88 (0.65-1.20)  
2012-2013 797 138 17.3% 1   
 
† LRT for the overall association of the variable with ART adherence 




Table 4: Univariable and multivariable logistic regression estimates of odds ratios for each stigma variable and ART adherence 
  ART adherence Unadjusted models Adjusted models§ Adjusted models¶ 
  n/N † %  OR 95% CI  Pw aOR 95% CI  Pw aOR 95% CI  Pw 
 Total Study Population  N=2020   analysis restricted to n=1888‡ 
Experienced stigma in the community              
No  201/1468 13.7% 1   1   1   
Yes 110/519 21.2% 1.68 (1.29-2.19) <0.001 1.65 (1.25-2.18) <0.001 1.63 (1.21-2.19) 0.001 
Experienced stigma in health settings              
No 290/1844 15.7% 1   1   1   
Yes 27/152 17.8% 1.19 (0.76-1.86) 0.44 1.38 (0.87-2.20) 0.17 1.05 (0.64-1.72) 0.86 
Internalised Stigma               
No  228/1552 14.7% 1   1   1   
Yes 87/434 20.0% 1.51 (1.15-2.00) 0.004 1.50 (1.12-2.01) 0.007 1.31 (0.96-1.79) 0.09 
Zambia N=1099   analysis restricted to n=1034‡ 
Experienced stigma in the community              
No  106/764 13.9% 1   1   1   
Yes 75/317 23.7% 1.89 (1.35-2.65) <0.001 1.98 (1.38-2.83) <0.001 2.03 (1.40-2.94) <0.001 
Experienced stigma in health settings              
No 174/1020 17.1% 1   1   1   
Yes 11/66 16.7% 0.99 (0.51-1.94) 0.98 1.10 (0.55-2.22) 0.79 0.80 (0.39-1.65) 0.54 
Internalised Stigma               
No  125/819 15.3% 1   1   1   
Yes 58/257 22.6% 1.62 (1.13-2.31) 0.008 1.67 (1.15-2.44) 0.007 1.44 (0.97-2.14) 0.07 
South Africa  N=921   analysis restricted to n=854‡ 
Experienced stigma in the community              
No  95/704 13.5% 1   1   1   
Yes 35/202 17.3% 1.32 (0.85-2.05) 0.22 1.21 (0.76-1.93) 0.43 1.01 (0.58-1.74) 0.98 
Experienced stigma in health settings              
No 116/824 14.1% 1   1   1   
Yes 16/86 18.6% 1.45 (0.80-2.64) 0.22 1.67 (0.89-3.13) 0.11 1.66 (0.79-3.47) 0.18 
Internalised Stigma               
No  103/733 14.1% 1   1   1   
Yes 29/177 16.4% 1.34 (0.85-2.11) 0.21 1.41 (0.87-2.27) 0.16 1.31 (0.78-2.21) 0.30 
†     n=non-adherent; N=total individuals reporting ever starting ART 
‡    analysis restricted to respondents with complete data on community/triplet, gender, age, education, wealth, mobility, alcohol and all stigma variables 
§    adjusted for community/triplet, gender, age, education, wealth, mobility, alcohol 
¶    adjusted for community/triplet, gender, age, education, wealth, mobility, alcohol and experienced stigma (internalised stigma adjusted for community and health setting stigma; health setting stigma adjusted for    
community stigma; community stigma adjusted for health setting stigma 
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